title: Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
authors.forename: V
authors.initials: V
authors.lastname: Pitini
authors.forename: C
authors.initials: C
authors.lastname: Arrigo
authors.forename: G
authors.initials: G
authors.lastname: Aloi
authors.forename: C
authors.initials: C
authors.lastname: Micali
authors.forename: G
authors.initials: G
authors.lastname: La Gattuta
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003907:Dexamethasone; D004317:Doxorubicin; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000628:therapy; D016879:Salvage Therapy / Q000379:methods*; D013792:Thalidomide / Q000627:therapeutic use*; D014750:Vincristine
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D008558:Melphalan